Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA)

Diabetes Care

Volumn 33, Issue 12, 2010, Pages 2531-2537

  Mishra, Nishant Kumar ^a   Davis, Stephen M ^b   Kaste, Markku ^c   Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FIBRINOLYTIC THERAPY; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANKIN SCALE;

ADULT; AGED; AGED, 80 AND OVER; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951705796     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1125     Document Type: Article

References (25)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-1329
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke.NEngl J Med 1995; 333(24):1581-1587
3. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 2007;27(3):435-451
4. Schurr A. Bench-to-bedside review: a possible resolution of the glucose paradox of cerebral ischemia. Crit Care 2002;6(4):330-334 (Pubitemid 34863701)
5. Kruyt ND, Biessels GJ, Devries JH, Roos YB. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol 2010;6(3):145-155
6. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006;37(12):2957-2962 (Pubitemid 44900816)
7. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic Therapy in Acute Ischemic Stroke Study Investigators. Stroke 2000;31(4):811-816 (Pubitemid 30198420)
8. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282(21):2019-2026
9. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352(9136):1245-1251 (Pubitemid 28470336)
10. Committee for Proprietary Medicinal Products for the European Agency for the Evaluation of Medicinal Products. Summary information on a referral opinion following an arbitration persuant to article 29 of directive 2001/83/ECfor Actilyse [article online],2002. Available at http://www.ema.europa.eu/docs/en- GB/document-library/referrals-document/actilyse-29/WC500010327.pdf. Accessed on 14 May 2010
11. Rubiera M, Ribo M, Santamarina E, Maisterra O, Delgado-Mederos R, Delgado P, Ortega G, Alvarez-Sabin J, Molina CA. Is it time to reassess the SITS-MOST criteria for thrombolysis? A comparison of patients with and without SITS-MOST exclusion criteria. Stroke 2009;40(7):2568-2571
12. Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, Fisher M, Gregson BA, Grotta J, Hacke W, Hennerici MG, Hommel M, Kaste M, Marler JR, Sacco RL, Teal P, Wahlgren NG, Warach S, Weir CJ, Lees KR. The Virtual International Stroke Trials Archive. Stroke 2007;38(6):1905-1910 (Pubitemid 46847267)
13. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G, the SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369(9558):275-282
14. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products for the treatment of acute stroke [article online], 2001. Available at http://www.tga.gov.au/docs/pdf/euguide/ewp/ 056098en.pdf. Accessed 28 August 2010
15. Lees KR, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Ashwood T, Hardemark HG, Wasiewski W, Emeribe U, Zivin JA, the SAINT I Investigators. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke 2006;37(12):2970-2978
16. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2009;72(15):1310- 1315
17. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007;38(12):3205-3212 (Pubitemid 350175738)
18. Weimar C, Konig IR, Kraywinkel K, Ziegler A, Diener HC. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke 2004;35(1):158-162 (Pubitemid 38057612)
19. Pandhi N, Smith MA, Kind AJ, Frytak JR, Finch MD. The quality of diabetes care following hospitalization for ischemic stroke. Cerebrovasc Dis 2009;27(3):235-240
20. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat 2009;8(1):50-61
21. Bluhmki E, Windeler J, Hacke W. [Neurological scales as endpoints in stroke studies. Aspects of statistical evaluation]. Nervenarzt 2000;71(10):797-801 [article in German]
22. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38(11):3055-3062 (Pubitemid 350035704)
23. Senn S, Julious S. Measurement in clinical trials: a neglected issue for statisticians?. Stat Med 2009;28(26):3189-209
24. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, the ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375(9727):1695-1703
25. Mishra NK, Ahmed N, Davalos A, Iversen HK, Soinne L, Wahlgren N, Lees KR. Post thrombolysis outcomes amongst patients with prior stroke and diabetes: controlled comparison of SITS international registry (SITS-ISTR) versus Virtual International Stroke Trials Archive (VISTA). Cerebrovasc Dis 2010;29(2):160